NCT00539890

Brief Summary

To compare the efficacy of prandial TI plus basal insulin versus prandial rapid acting, subcutaneous insulin plus basal insulin in subjects with type 2 diabetes who had an HbA1c \>7.0% and \<11.5%.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Nov 2005

Shorter than P25 for phase_3

Geographic Reach
1 country

33 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2005

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2006

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

October 3, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 5, 2007

Completed
Last Updated

October 14, 2009

Status Verified

October 1, 2009

First QC Date

October 3, 2007

Last Update Submit

October 12, 2009

Conditions

Outcome Measures

Primary Outcomes (1)

  • Mean change in HbA1c from baseline to treatment week 24

    24 weeks

Interventions

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • At least 2 years since diagnosis of type 2 diabetes mellitus
  • Received subcutaneous (sc) insulin for at least 3 months
  • Body Mass Index \<44 kg/m2
  • HbA1c\>7.0% and \<11.5%
  • Serum creatinine \<2.0 mg/dL for males and \<1.8 mg/dL for females
  • Baseline FVC and FEV1\>70% and \< 125% of predicted normal

You may not qualify if:

  • Significant hepatic disease (AST/ALT3 x ULN)
  • Diagnosis of Type 1 diabetes
  • Severe complications of diabetes
  • History of moderate to severe ketoacidosis within the past 3 months
  • Upper respiratory infection in the last 15 days or a lower respiratory infection in the past 30 days
  • Diagnosis of HIV
  • Positive serology for hepatitis B or C
  • COPD, emphysema, or asthma
  • Current smokers or smoking history within the past 6 months
  • Major psychiatric disorder precluding satisfactory completion of protocol
  • Clinically significant heart disease disease, stroke or heart attack within the past 6 months
  • Treatment with an investigational drug within 30 days
  • Previous treatment with Technosphere/Insulin
  • History of malignancy in the past 5 years except basal cell carcinoma
  • Anemia (hemoglobin \<10.5 g/dL for females and \<11.5 g/dL (for males)
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (33)

Ural State Medical Academy of Post-Graduate Education Municipal Clinical Hospital # 3

Chelyabinsk, RUS, 454021, Russia

Location

NHI Kemerovo Regional Clinical Hospital

Kemerovo, RUS, 650061, Russia

Location

NI Principal Military Clinical Hospital n a academician N.N. Burdenko of the Ministry of Defense

Moscow, RUS, 105229, Russia

Location

Moscow State Medico-Stomatological University City Hospital # 23

Moscow, RUS, 109240, Russia

Location

Russian State Medical University

Moscow, RUS, 109263, Russia

Location

Clinical Research Institute of Physic-Chemical Medicine Hospital # 29

Moscow, RUS, 111020, Russia

Location

NEI HPE Moscow State University of Medicine and Dentistry of FAHSD City Clinical Hospital #70

Moscow, RUS, 111399, Russia

Location

Russian State Medical University City Hospital # 4

Moscow, RUS, 113093, Russia

Location

Russian Academy of Medical Sciences National Research Ctr for Endocrinology Institute of Diabetes

Moscow, RUS, 117036, Russia

Location

Moscow Hospital of Glavmosstroy State Unitary Enterprise Medical Centre Medical Sanitary Unit #47

Moscow, RUS, 117192, Russia

Location

Russian State Medical University Central Clinical Hospital Russian Science Academy

Moscow, RUS, 117593, Russia

Location

Sechenov Moscow Medical Academy

Moscow, RUS, 119881, Russia

Location

Moscow Medical Academy

Moscow, RUS, 123478, Russia

Location

Unknown Facility

Moscow, RUS, 125315, Russia

Location

SIH of Moscow City Clinical Hopsital #81 Endocrinology and Diabetology

Moscow, RUS, 127644, Russia

Location

Moscow State Medical Stomatology University Municipal Hospital # 63 Endocrinology Diabetology

Moscow, RUS, 129090, Russia

Location

Moscow City Clinical Hospital # 20

Moscow, RUS, 129327, Russia

Location

Municipal Clinical Hospital #13

Moscow, RUS, 150062, Russia

Location

Nizhni Novgorod regional hospital na Semashko

Nizhny Novgorod, RUS, 603126, Russia

Location

St Petersburg NHI City Polytclinic #77 City Diabetological Center #4

Saint Petersburg, RUS, 193012, Russia

Location

Central Medical Sanitary Unit #122

Saint Petersburg, RUS, 194291, Russia

Location

SPb Diabetological Center

Saint Petersburg, RUS, 194354, Russia

Location

St Petersburg NHI Municipal Multi-Speciality Hospital # 2

Saint Petersburg, RUS, 194354, Russia

Location

St Petersburg Medical Academy St Elizabeth Hospital

Saint Petersburg, RUS, 195257, Russia

Location

Pavlov State Medical Univ of St Petersburg

Saint Petersburg, RUS, 197022, Russia

Location

City Outpatient Clinic # 34

Saint Petersburg, RUS, 197198, Russia

Location

TUV Medico-Military Academy

Saint Petersburg, RUS, 198013, Russia

Location

Center Diabetes LLC

Samara, RUS, 443067, Russia

Location

Saratov City Outpatient Clinic # 20

Saratov, RUS, 410038, Russia

Location

Saratov Medical University Faculty Therapy Chair Clinical Hospital # 3

Saratov, RUS, 410054, Russia

Location

NEI HPE Smolensk State Medical Academy of FAHSD RNHI Smolensk Regional Clinical Hospital

Smolensk, RUS, 214018, Russia

Location

MHI Clinical Hospital for Emergency Care na NV Soloviev

Yaroslavl, RUS, 150003, Russia

Location

Yaroslavl Regional Clinical Hospital

Yaroslavl, RUS, 150062, Russia

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Robert Baughman, PhD

    Mannkind Corporation

    STUDY DIRECTOR
0

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

October 3, 2007

First Posted

October 5, 2007

Study Start

November 1, 2005

Study Completion

July 1, 2006

Last Updated

October 14, 2009

Record last verified: 2009-10

Locations